Patents by Inventor Francesca Mancini

Francesca Mancini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Performance Measuring System Measuring Sustainable Development Relevant Properties Of An Object, and Method Thereof
    Publication number: 20230090136
    Abstract: Proposed is an automated measuring system for progress monitoring and steering of impacts of a complex system to world environment and ecosystem induced by environmental-human linkages and for quantitative measuring of effects of applied risk-transfer structures to said environmental-human linkages induced by risk-transfer-SDG linkages measuring quantifying distances of progresses toward at least one of a predefined sustainable development goal with and without applying said risk-transfer structures.
    Type: Application
    Filed: September 14, 2022
    Publication date: March 23, 2023
    Applicant: Swiss Reinsurance Company Ltd.
    Inventors: Salomon Rudolf BILLETER, Xi FAN, Francesca MANCINI, Alicia MONTOYA
  • PEPTIDES HAVING INHIBITORY ACTIVITY ON NEURONAL EXOCYTOSIS
    Publication number: 20220296489
    Abstract: The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 22, 2022
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.
    Inventors: Francesca MANCINI, Isabel DEVESA GINER, Antonio FERRER MONTIEL, Gregorio FERNANDEZ BALLESTER, Giorgina MANGANO, Cristina BARTELLA
  • PEPTIDES HAVING INHIBITORY ACTIVITY ON MUSCARINIC RECEPTOR M3
    Publication number: 20220142898
    Abstract: Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.
    Type: Application
    Filed: June 11, 2019
    Publication date: May 12, 2022
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. S.p.A.
    Inventors: Francesca MANCINI, Isabel DEVESA GINER, Antonio FERRER MONTIEL, Gregorio FERNANDEZ BALLESTER, Giorgina MANGANO, Cristina BARTELLA
  • 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    Patent number: 10160746
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: December 25, 2018
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
  • Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    Patent number: 9700551
    Abstract: The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 11, 2017
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro', Rosella Ombrato, Francesca Mancini
  • 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
    Publication number: 20170174657
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.P.A.
    Inventors: Maria Alessandra ALISI, Nicola CAZZOLLA, Patrizia DRAGONE, Guido FURLOTTI, Caterina MAUGERI, Rosella OMBRATO, Francesca MANCINI
  • 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
    Publication number: 20170157121
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 8, 2017
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra ALISI, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
  • 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    Patent number: 9611249
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 4, 2017
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
  • NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
    Publication number: 20160045485
    Abstract: The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
    Type: Application
    Filed: August 13, 2015
    Publication date: February 18, 2016
    Applicant: Aziende Chimiche Riunite Angelini Francesco A.C.R. A.F. S.P.A.
    Inventors: Maria Alessandra ALISI, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro', Rosella Ombrato, Francesca Mancini
  • Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
    Patent number: 9163013
    Abstract: 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 20, 2015
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro′, Rosella Ombrato, Francesca Mancini
  • 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
    Publication number: 20150057294
    Abstract: The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.
    Type: Application
    Filed: February 7, 2013
    Publication date: February 26, 2015
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Patrizia Dragone, Guido Furlotti, Caterina Maugeri, Rosella Ombrato, Francesca Mancini
  • NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS
    Publication number: 20140378455
    Abstract: 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-33) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
    Type: Application
    Filed: February 8, 2013
    Publication date: December 25, 2014
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.
    Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro', Rosella Ombrato, Francesca Mancini